VI

VivoSim Labs, Inc.

VIVS · Nasdaq

VivoSim Labs, Inc. (VIVS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for VivoSim Labs, Inc. in 2026. The next earnings report is expected on November 5, 2026.

Earnings calendar

Next earnings date

05 Nov 2026

In 76 days

EPS estimate

-2.04

Revenue estimate

54.0K

Past earnings

13 Aug 2026
EPS actual
—
estimate -2.04
Revenue actual
—
estimate 54.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Aug 2026
EPS actual
—
estimate -2.04
Revenue actual
—
estimate 54.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
11 Aug 2026
EPS actual
—
estimate -2.04
Revenue actual
—
estimate 54.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
10 Aug 2026
EPS actual
—
estimate -2.04
Revenue actual
—
estimate 54.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
07 Aug 2026
EPS actual
—
estimate -2.04
Revenue actual
—
estimate 54.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
06 Aug 2026
EPS actual
—
estimate -2.04
Revenue actual
—
estimate 54.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
14 Jul 2026
EPS actual
—
estimate -2.04
Revenue actual
—
estimate 54.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
29 May 2026
EPS actual
—
estimate -2.04
Revenue actual
—
estimate 54.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
11 Feb 2026
EPS actual
—
estimate -2.40
Revenue actual
—
estimate 50.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
06 Nov 2025
EPS actual
—
estimate -2.28
Revenue actual
—
estimate 50.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Keith E. Murphy
Employees
14
IPO date
14 Feb 2012
ISIN
US68620A3023
Website
vivosim.ai

Frequently asked questions

When does VivoSim Labs, Inc. (VIVS) next report earnings?

VivoSim Labs, Inc. (VIVS) is scheduled to report earnings on November 5, 2026.

What was VivoSim Labs, Inc.'s most recent earnings date?

VivoSim Labs, Inc. (VIVS) last reported earnings on August 13, 2026.

Where is VivoSim Labs, Inc. stock listed?

VivoSim Labs, Inc. (VIVS) is listed on Nasdaq.